Positron Corporation Secures Multiple PET-CT Orders from Leading Nuclear Cardiologist Practices

Positron Corporation, a leader in molecular imaging technology and services, announced the sale of four (4) PET-CT 64-slice scanners, along with associated long-term services agreements, to three distinguished nuclear cardiology practices led by nationally recognised physicians specialising in advanced cardiovascular diagnostics and interventional care.

These new customer engagements underscore the adoption of Positron’s next-generation PET-CT technology and comprehensive services solution. Nuclear cardiology practices are increasingly selecting Positron not only for its advanced imaging capabilities, but also for its fully integrated clinical, technical, and training support that is designed to ensure operational reality, efficiency and long-term value.

“As cardiac PET continues to replace legacy imaging modalities, providers are increasingly seeking solutions that deliver both superior clinical performance and sustainable, viable economics,” said Adel Abdullah, President and Chairman of Positron Corporation. “This continued adoption reflects growing confidence in the modality and recognition of Positron’s ability to support practices with advanced PET-CT technology, exceptional service, and a true partnership-oriented approach.”

Engineered to optimise both clinical outcomes and operational efficiency, Positron’s PET-CT scanners provide high-resolution anatomic and functional imaging for both cardiac and oncology applications. Key features include a 72cm wide-bore gantry for enhanced patient comfort, high-sensitivity detector technology that supports reduced radiation exposure, and a compact footprint, the smallest and lightest in its class, making it ideal for most clinical environments.

Positron’s advanced data acquisition capabilities deliver fast, high-precision imaging, enhancing diagnostic confidence while expanding the scope of studies physicians can perform, from myocardial perfusion to tumour detection and neurological assessments.